However, the combined presence of high sPD-L1 and low mHLA-DR levels at the end of the first week identified a subgroup of patients with particularly poor clinical outcomes.<h4>Conclusions</h4>These findings highlight the potential of sPD-L1 as a clinically relevant biomarker in the context of sepsis immunopathology. Here, SPDL1 is linked to Sepsis.